Implantable monitor of vulnerable plaque and other disease states

• US 20050009074A1
• Filed: 07/01/2004
• Published: 01/13/2005
• Est. Priority Date: 07/07/2003
• Status: Abandoned Application

• Current Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Original Assignee: Medtronic Vascular, Inc. (Medtronic Plc)
• Inventors: Thompson, David L.
• Application Number:
  US10/884,249
• Publication Number:
  US 20050009074A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 49/0004 Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
• CPC Class Codes: G01N 33/5302 Apparatus specially adapted for immunological test procedures

Abstract

A method and implantable devices for monitoring a disease state in a patient. The method includes providing a monitor for C-reactive protein and implanting the monitor in the patient. At least one molecule binds to the C-reactive protein. A blood concentration of the C-reactive protein is determined based on the binding. A first implantable device includes a housing and a substrate including at least one molecule directed to the C-reactive protein. The first device further includes a detector adapted for measuring binding of the C-reactive protein to the molecule. A second implantable device includes implantable means for monitoring a C-reactive protein and means for binding the C-reactive protein. The second device further includes means for determining a blood concentration of the C-reactive protein based on the binding means.

Claims

1. A method of monitoring a disease state in a patient, the method comprising:

providing a monitor for C-reactive protein;

implanting the monitor in the patient;

binding at least one molecule to the C-reactive protein; and

determining a blood concentration of the C-reactive protein based on the binding.

2. The method of claim 1 wherein the disease state comprises at least one condition selected from a group consisting of vulnerable plaque, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn'"'"'s disease, acute pancreatitis, cardiac infarction, septicemia, infection, meningitis, pneumonia, tissue injury, burn, wound, trauma, and an inflammatory condition.

3. The method of claim 1 wherein the at least one molecule comprises at least one molecule selected from a group consisting of a C-reactive binding protein, an immunoglobulin, an Fc class receptor, a major histocompatability complex molecule, a phosphocoline, a CD, a polysaccharide, a polycation, a binding molecule, a binding protein, a membrane protein, a polynucleotide, an antisense polynucleotide, a modified polynucleotide, and a biotinylated molecule.

4. The method of claim 1 wherein the binding of the at least one molecule to the C-reactive protein comprises a reversible binding.

5. The method of claim 1 wherein determining the blood concentration of the C-reactive protein comprises one or more determinations selected from a group consisting of repeated determinations, continuous determinations, intermittent determinations, and running average determinations.

6. The method of claim 1 wherein determining the blood concentration of the C-reactive protein comprises detecting electromagnetic radiation or sonic energy.

7. The method of claim 6 wherein the electromagnetic radiation is selected from a group consisting of radio wave radiation, microwave radiation, infra-red radiation, near infra-red radiation, visible light radiation, ultraviolet radiation, x-ray radiation, beta radiation, and fluorescence radiation.

8. The method of claim 1 further comprising applying electromagnetic radiation or sonic energy directed at the at least one molecule.

9. The method of claim 8 wherein the electromagnetic radiation is selected from a group consisting of radio wave radiation, microwave radiation, infra-red radiation, near infra-red radiation, visible light radiation, ultraviolet radiation, x-ray radiation, beta radiation, and fluorescence radiation.

10. The method of claim 1 further comprising communicating the determined blood concentration of the C-reactive protein through the Internet.

11. The method of claim 1 further comprising communicating the determined blood concentration of the C-reactive protein to the patient.

12. An implantable device for monitoring a disease state in a patient, the device comprising:

a housing;

a substrate including at least one molecule directed to the C-reactive protein; and

a detector adapted for measuring binding of the C-reactive protein to the molecule.

13. The device of claim 12 wherein the disease state comprises at least one condition selected from a group consisting of vulnerable plaque, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn'"'"'s disease, acute pancreatitis, cardiac infarction, septicemia, infection, meningitis, pneumonia, tissue injury, burn, wound, trauma, and an inflammatory condition.

14. The device of claim 12 wherein the substrate comprises an underlying surface including the at least one molecule disposed thereon.

15. The device of claim 12 wherein the at least one molecule comprises a particle.

16. The device of claim 15 wherein the particle comprises a micro-particle of about 0.5 to 10.0 micrometers in diameter.

17. The device of claim 15 wherein the particle comprises a nano-particle of about 10 to 200 nanometers in diameter.

18. The device of claim 12 wherein the molecule comprises at least one molecule selected from a group consisting of a C-reactive binding protein, an immunoglobulin, an Fc class receptor, a major histocompatability complex molecule, a phosphocoline, a CD, a polysaccharide, a polycation, a binding molecule, a binding protein, a membrane protein, a polynucleotide, an antisense polynucleotide, a modified polynucleotide, and a biotinylated molecule.

19. The device of claim 12 wherein the detector measures the binding of the C-reactive protein to the at least one molecule continuously or intermittently.

20. The device of claim 12 wherein the detector detects electromagnetic radiation or sonic energy.

21. The device of claim 20 wherein the electromagnetic radiation is selected from a group consisting of radio wave radiation, microwave radiation, infra-red radiation, near infra-red radiation, visible light radiation, ultraviolet radiation, x-ray radiation, beta radiation, and fluorescence radiation.

22. The device of claim 12 further comprising a generator operably coupled to the detector for applying electromagnetic radiation or sonic energy directed to the at least one molecule.

23. The device of claim 22 wherein the electromagnetic radiation is selected from a group consisting of radio wave radiation, microwave radiation, infra-red radiation, near infra-red radiation, visible light radiation, ultraviolet radiation, x-ray radiation, beta radiation, and fluorescence radiation.

24. The device of claim 12 wherein the monitor is operably coupled to the Internet.

25. The device of claim 12 further comprising at least one lead extending from the body and adapted for positioning at a blood sampling site.

27. The device of claim 12 further comprising:

an input/output circuit operably coupled to the detector; and

a micro-computer circuit operably coupled to the input/output circuit for determining a blood concentration of the C-reactive protein based on the measured binding of the C-reactive protein to the at least one molecule.

28. The device of claim 27 wherein the micro-computer circuit determines a running average of the C-reactive protein blood concentration.

29. The device of claim 12 further comprising a patient alarm operably coupled to the monitor for indicating the monitored disease state.

30. The device of claim 26 wherein the patient alarm comprises at least one predetermined threshold level.

31. An implantable device for monitoring a disease state in a patient, the device comprising:

implantable means for monitoring a C-reactive protein;

means for binding the C-reactive protein; and

means for determining a blood concentration of the C-reactive protein based on the binding means.

32. The device of claim 31 further comprising means for applying electromagnetic radiation or sonic energy directed at the molecule.

33. The device of claim 31 further comprising means for communicating the determined blood concentration of the C-reactive protein external to the patient.